AnxietyNCT01372787
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
An observational study of Anxiety and Fatigue, run by Gynecologic Oncology Group at 144 sites in United States.
Trial summary
This clinical trial studies the quality of life and care needs of patients with persistent or recurrent ovarian cancer, fallopian tube cancer, or peritoneal cancer. Studying quality of life in patients with cancer may help determine the effects of gynecologic cancer and may help improve the quality of life for future… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Anxiety, Fatigue, Nausea and Vomiting
- What is being tested?
- Assessment of Therapy Complications, Medical Chart Review and Quality-of-Life Assessment
- Type of treatment
- Surgery or procedure
- How many people
- 103 participants
- Where
- 144 sitesUnited States
- Study dates
- 12 Apr 2011to 31 Jan 2014
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with persistent or recurrent epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer
- Platinum-resistant (less than 6 months from date of last platinum therapy to date of first evidence of recurrent or persistent disease) disease as measured by any of the following:
- Imaging
- Physical exam
- CA-125 that is twice the upper limit of normal on two occasions with at least one week apart
- No patients who have platinum resistant or refractory disease after more than 6 months since prior therapy
Show all 14Show fewer
- Criteria for patients on cancer therapy (e.g., chemotherapy, non-cytotoxic regimens, hormone therapy, or radiation therapy) include recurrent or persistent disease defined as having measurable disease per RECIST (Version 1.1)
- Patients not on chemotherapy are also eligible and are not required to have RECIST criteria
- Life expectancy of at least 6 months
- Patients with any performance status, yet with the ability to verbally consent and participate in the first assessment
- Study measures will be administered in the office/clinic setting, or for study participants who are unable to attend clinics, via telephone or mail (telephone is the preferred back-up means)
- Patients may have or have had a prior non-gynecologic malignancy within 5 years prior to study enrollment; however, they must have completed all treatments for the disease and have no evidence of disease at the time of enrollment, and ovarian, peritoneal, or fallopian tube cancer must be the primary life-threatening diagnosis
- Patient must be able to read and write English
- No patients receiving chemotherapy for platinum-sensitive ovarian cancer, peritoneal, or fallopian tube cancer
Who cannot join
None listed.
Trial locations and contacts
144 sites in 1 country.
144 sites in 1 country
United States144 sites
Summa Akron City Hospital/Cooper Cancer Center
Akron, Ohio, 44304
Cleveland Clinic Akron General
Akron, Ohio, 44307
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87102
McFarland Clinic PC - Ames
Ames, Iowa, 50010
Michigan Cancer Research Consortium NCORP
Ann Arbor, Michigan, 48106
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
University of Colorado Hospital
Aurora, Colorado, 80045
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
State University of New York Downstate Medical Center
Brooklyn, New York, 11203
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, 28203
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Chattanooga's Program in Women's Oncology
Chattanooga, Tennessee, 37403
Northwestern University
Chicago, Illinois, 60611
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
Case Western Reserve University
Cleveland, Ohio, 44106
Riverside Methodist Hospital
Columbus, Ohio, 43214
Atrium Health Cabarrus/LCI-Concord
Concord, North Carolina, 28025
Mercy Hospital
Coon Rapids, Minnesota, 55433
Beaumont Hospital ? Dearborn
Dearborn, Michigan, 48124
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Iowa-Wide Oncology Research Coalition NCORP
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201
Ascension Saint John Hospital
Detroit, Michigan, 48236
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Elkhart Clinic
Elkhart, Indiana, 46514-2098
Michiana Hematology Oncology PC-Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201
Hurley Medical Center
Flint, Michigan, 48503
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Unity Hospital
Fridley, Minnesota, 55432
Genesys Regional Medical Center
Grand Blanc, Michigan, 48439
Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, 29615
Hartford Hospital
Hartford, Connecticut, 06102
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, 06105
Sudarshan K Sharma MD Limited-Gynecologic Oncology
Hinsdale, Illinois, 60521
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Memorial Hermann Texas Medical Center
Houston, Texas, 77030
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Allegiance Health
Jackson, Michigan, 49201
Saint Dominic-Jackson Memorial Hospital
Jackson, Mississippi, 39216
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazoo, Michigan, 49048
University of Kansas Cancer Center
Kansas City, Kansas, 66160
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
Research Medical Center
Kansas City, Missouri, 64132
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Community Howard Regional Health
Kokomo, Indiana, 46904
IU Health La Porte Hospital
La Porte, Indiana, 46350
Sparrow Hospital
Lansing, Michigan, 48912
Women's Cancer Center of Nevada
Las Vegas, Nevada, 89169
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Baptist Health Lexington
Lexington, Kentucky, 40503
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
Holy Family Memorial Hospital
Manitowoc, Wisconsin, 54221
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Bay Area Medical Center
Marinette, Wisconsin, 54143
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio, 44060
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Michiana Hematology Oncology PC-Mishawaka
Mishawaka, Indiana, 46545
Saint Joseph Regional Medical Center-Mishawaka
Mishawaka, Indiana, 46545
Morristown Medical Center
Morristown, New Jersey, 07960
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
The Hospital of Central Connecticut
New Britain, Connecticut, 06050
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Saint Luke's South Hospital
Overland Park, Kansas, 66213
Paoli Memorial Hospital
Paoli, Pennsylvania, 19301
Advocate Lutheran General Hospital
Park Ridge, Illinois, 60068
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
Michiana Hematology Oncology PC-Plymouth
Plymouth, Indiana, 46563
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Lake Huron Medical Center
Port Huron, Michigan, 48060
Maine Medical Center-Bramhall Campus
Portland, Maine, 04102
Kansas City NCI Community Oncology Research Program
Prairie Village, Kansas, 66208
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
Women and Infants Hospital
Providence, Rhode Island, 02905
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Delbert Day Cancer Institute at PCRMC
Rolla, Missouri, 65401
William Beaumont Hospital-Royal Oak
Royal Oak, Michigan, 48073
Ascension Saint Mary's Hospital
Saginaw, Michigan, 48601
Lakeland Medical Center Saint Joseph
Saint Joseph, Michigan, 49085
Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, 55416
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Cancer Center of Kansas - Salina
Salina, Kansas, 67401
Greenville Health System Cancer Institute-Seneca
Seneca, South Carolina, 29672
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Michiana Hematology Oncology PC-South Bend
South Bend, Indiana, 46601
South Bend Clinic
South Bend, Indiana, 46617
Northern Indiana Cancer Research Consortium
South Bend, Indiana, 46628
Greenville Health System Cancer Institute-Spartanburg
Spartanburg, South Carolina, 29307
Baystate Medical Center
Springfield, Massachusetts, 01199
Cancer Research for the Ozarks NCORP
Springfield, Missouri, 65804
Mercy Hospital Springfield
Springfield, Missouri, 65804
CoxHealth South Hospital
Springfield, Missouri, 65807
Washington University School of Medicine
St Louis, Missouri, 63110
Lakeview Hospital
Stillwater, Minnesota, 55082
Scott and White Memorial Hospital
Temple, Texas, 76508
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma, 74146
Carle Cancer Center
Urbana, Illinois, 61801
Ridgeview Medical Center
Waconia, Minnesota, 55387
Saint John Macomb-Oakland Hospital
Warren, Michigan, 48093
Cancer Center of Kansas - Wellington
Wellington, Kansas, 67152
Michiana Hematology Oncology PC-Westville
Westville, Indiana, 46391
Associates In Womens Health
Wichita, Kansas, 67208
Cancer Center of Kansas-Wichita Medical Arts Tower
Wichita, Kansas, 67208
Cancer Center of Kansas - Wichita
Wichita, Kansas, 67214
Via Christi Regional Medical Center
Wichita, Kansas, 67214
Wichita NCI Community Oncology Research Program
Wichita, Kansas, 67214
Rice Memorial Hospital
Willmar, Minnesota, 56201
Cancer Center of Kansas - Winfield
Winfield, Kansas, 67156
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
University of Massachusetts Memorial Health Care
Worcester, Massachusetts, 01605
Lankenau Medical Center
Wynnewood, Pennsylvania, 19096
Main Line Health NCORP
Wynnewood, Pennsylvania, 19096
About this study
Official title: Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
This clinical trial studies the quality of life and care needs of patients with persistent or recurrent ovarian cancer, fallopian tube cancer, or peritoneal cancer. Studying quality of life in patients with cancer may help determine the effects of gynecologic cancer and may help improve the quality of life for future cancer survivors.
Read the detailed description
PRIMARY OBJECTIVES:
- To determine the prevalence and severity of patient-reported symptoms in patients with platinum-resistant ovarian, fallopian tube, and peritoneal cancers at study entry and at three and six months post-enrollment.
SECONDARY OBJECTIVES:
- To explore the unmet needs of these women at study entry and at three and six months post-enrollment (Exploratory) II. To explore the overall quality-of-life (QOL) of these women at study entry and at three and six months post enrollment. (Exploratory) III. To explore the relationship between patient-reported symptoms and overall QOL, current cancer therapy (yes/no), and treatment responses (if on cancer therapy). (Exploratory)
OUTLINE: This is a multicenter study.
Patients complete the Needs at the End-of-Life Screening Tool (NEST), the Functional Assessment of Cancer Therapy ? Ovarian (FACT-O), the FACIT-Fatigue Subscale (FACIT-F), the National Comprehensive Cancer Network (NCCN) FACT Ovarian Symptom Index-18 (NFOSI-18), the FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort, and the FACT/GOG-Neurotoxicity (FACT/GOG-NTX) Scale quality-of-life questionnaires at baseline and at 3 and 6 months during office or clinic visits or via telephone or mail. Patients' demographic and therapy information, such as current age, ethnicity, marital status, employment status, prior chemotherapy regimens/cancer treatment, disease status (if available), performance status, patient care information, and current cancer therapy are also collected.
After completion of study participation, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
- Conditions
- Anxiety, Fatigue, Nausea and Vomiting, Neurotoxicity Syndrome, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Being tested
- Assessment of Therapy Complications, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
- Medical subject headings
- Anxiety Disorders, Fatigue, Nausea, Vomiting, Neurotoxicity Syndromes, Fallopian Tube Neoplasms, Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Assessment of Therapy ComplicationsProcedure or surgery
Ancillary studies
Medical Chart ReviewOther
Also called Chart Review
Ancillary studies
Quality-of-Life AssessmentOther
Also called Quality of Life Assessment
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Arm I | Not described Receives: Procedure: Assessment of Therapy Complications; Other: Medical Chart Review; Other: Quality-of-Life Assessment; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence and severity of patient-reported symptoms as measured by the NFOSI-18, the FACIT-F subscale, and the FACT/GOG-AD and NTX subscales
Assessed at baseline, and at 3 and 6 months. The prevalence of a patient-reported symptom will be determined by the percentage of living patients reporting the presence of a symptom at the assessment time point.
Measured: Up to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2011 (estimated)
- Study start12 Apr 2011
- Primary completion31 Jan 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AnxietyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Enrolment
- 103 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gynecologic Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Vivian E von Gruenigen, Principal investigator, NRG Oncology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01372787
- Sponsor's protocol ID
- GOG-0267
- Other IDs
- NCI-2011-02547, CDR0000701477, GOG-0267, GOG-0267, GOG-0267, U10CA101165
- Status last verified
- Mar 2019
- First submitted
- 11 Jun 2011
- Last updated
- 12 Mar 2019
- Results posted
- No